Warts

Table of Contents

1. What are Warts?
2. HPV Types and Wart Categories
3. How HPV Transforms Keratinocytes
4. Symptoms and Clinical Appearance
5. Diagnosis
6. Treatment Options
7. Natural and Experimental Approaches
8. Immune Clearance and Spontaneous Resolution
9. Complications
10. Prevention and Contagion Control
11. Key Research Papers
12. PubMed Searches
13. Connections
14. Featured Videos

What are Warts?

Warts are benign epithelial skin growths caused by infection with human papillomavirus (HPV), a small double-stranded DNA virus in the family Papillomaviridae. There are more than 200 HPV genotypes; different types infect different anatomical sites and cause distinct clinical presentations ranging from innocuous common hand warts to genital warts and, in a minority of high-risk HPV types, precancerous and cancerous changes of the cervix, anus, oropharynx, and other mucosa.

Warts are among the most common skin conditions worldwide, affecting approximately 10% of the general population at any time and up to 20–33% of children and teenagers. Most cutaneous warts are benign and self-limiting, with the immune system clearing the infection in months to a few years. Treatment is pursued mainly for pain, cosmesis, and preventing spread.

HPV Types and Wart Categories

Common Warts (Verruca Vulgaris)

• HPV types: Primarily HPV-2 and HPV-4; also HPV-1, 27, 57.
• Sites: Dorsal hands, fingers, periungual area (around and under nails), knees, elbows.
• Appearance: Rough, dome-shaped papule with a hyperkeratotic surface. 1 mm to over 1 cm. Black dots (thrombosed capillaries, often called "wart seeds") within the surface are characteristic and help distinguish warts from calluses and corns.
• Mosaic warts: Clusters of multiple small warts coalescing on the palm or sole.

Plantar Warts (Verruca Plantaris)

• HPV types: Primarily HPV-1 (myrmecia, deeply endophytic), HPV-2 and HPV-4 (mosaic type).
• Sites: Soles of the feet, pressure-bearing points (ball of the foot, heel).
• Appearance: Unlike hand warts, plantar warts grow inward (endophytically) due to weight-bearing pressure, forming a deep, painful callus-like lesion. Loss of dermatoglyphic (skin line) pattern through the lesion — skin lines are interrupted in warts but pass over calluses.
• Pain: Can be intensely painful with weight-bearing. Depth and tenderness differentiates them from simple calluses.
• HPV-1 type (myrmecia) has a characteristic single deep crater-like appearance with a translucent center; highly painful.

Flat Warts (Verruca Plana)

• HPV types: HPV-3 and HPV-10; also HPV-28, 49.
• Sites: Face (forehead, cheeks), dorsal hands, shins, neck. Commonly spread by shaving.
• Appearance: Flat-topped, smooth, flesh-colored or lightly pigmented papules, typically 1–4 mm; often numerous (dozens to hundreds) and in linear distribution (Koebner phenomenon — warts follow scratch marks from autoinoculation).
• Often mistaken for acne on the face; distinguished by flat top, smooth surface, and grouped distribution.

Genital and Anogenital Warts (Condyloma Acuminata)

• HPV types: HPV-6 and HPV-11 cause ~90% of genital warts (low-risk, non-oncogenic types). High-risk types HPV-16 and HPV-18 cause cervical cancer and other anogenital/oropharyngeal cancers but do NOT cause visible condylomata.
• Sites: Vulva, vagina, cervix, penis (shaft and glans), scrotum, perianal skin, anal canal; occasionally urethra and oral cavity.
• Appearance: Soft, flesh-colored, exophytic papules or plaques; may be single or coalescing into cauliflower-like masses. Often asymptomatic but may cause itch, burning, or bleeding.
• Transmission: Sexually transmitted in adults; neonatal transmission during delivery can cause recurrent respiratory papillomatosis (laryngeal warts in children).

Filiform Warts

• Slender, finger-like projections; occur on the face, eyelids, lips, and neck. HPV-2, 3, 27.
• Often spread by facial grooming (shaving, tweezing).

Epidermodysplasia Verruciformis (EV)

• Rare genetic immunodeficiency (EVER1/EVER2/CIB1 gene mutations) causing unusual susceptibility to cutaneous HPV types (HPV-5, 8, 47) that cause plane wart–like lesions and pityriasis versicolor–like macules with a significant (~30–50%) lifetime risk of skin squamous cell carcinoma on sun-exposed sites.

How HPV Transforms Keratinocytes

• Entry and latency: HPV enters the epidermis through microtrauma (cuts, abrasions) and infects basal keratinocytes at the dermal-epidermal junction. The viral genome persists as an extrachromosomal episome in the basal cell nucleus.
• Viral replication linked to keratinocyte differentiation: As infected basal cells divide and differentiate toward the surface, HPV capitalizes on the differentiation-dependent expression of viral genes. Early proteins (E6, E7) are expressed first to drive the cell cycle; late proteins (L1, L2 — capsid proteins) are expressed only in suprabasal, terminally differentiating keratinocytes.
• E6 and E7 oncoproteins (high-risk HPV types): In high-risk HPV types (16, 18), E6 targets p53 for proteasomal degradation (abrogating apoptosis) and E7 binds and inactivates retinoblastoma protein (pRb), releasing E2F transcription factors that drive S-phase entry. These activities allow viral DNA amplification but also enable neoplastic transformation if HPV integrates into the host genome (a step toward cervical cancer).
• Low-risk types (6, 11) and benign warts: Low-risk HPV E6/E7 proteins have much weaker binding affinity for p53 and pRb. Infection remains productive (making virus) rather than transforming — hence condylomata caused by HPV-6/11 are almost always benign.
• Immune evasion: HPV suppresses keratinocyte MHC-I expression and interferon signaling, allowing the virus to replicate for months without triggering antiviral immunity. This immune evasion explains why warts can persist for years — but when the immune system eventually recognizes HPV antigens, clearance is often rapid.
• Hyperproliferation: E6/E7 drive excess keratinocyte proliferation, leading to the characteristic thickened, verrucous surface. Acanthosis (thickening of the stratum spinosum) and papillomatosis (upward proliferation of rete ridges) are the histological signatures.

Symptoms and Clinical Appearance

• Pain and tenderness: Common warts on hands are rarely painful unless periungual (under nails, exquisitely painful). Plantar warts on pressure points cause pain with walking; pain disappears with unweighting the foot. Flat warts are usually asymptomatic.
• Itch: Flat warts on the face and body can itch, especially when multiple. Genital warts may itch and be associated with moisture-related irritation.
• Bleeding: Periungual warts and plantar warts may bleed when traumatized. Genital warts can bleed with intercourse or bowel movements.
• Koebner phenomenon (isomorphic response): Warts spread along lines of trauma — a diagnostic clue in flat warts showing a linear array along a scratch mark or shaving line.
• Autoinoculation: Picking, biting, or shaving over warts disperses virus and creates satellite lesions in adjacent skin (nail-biting spreads periungual warts to lips; shaving spreads flat warts across the beard area).

Diagnosis

Warts are primarily diagnosed clinically by their characteristic appearance. Dermoscopy and histopathology are used in uncertain cases.

Clinical Clues

• Interrupted dermatoglyphics: Skin lines (fingerprints, palm ridges, sole patterns) are disrupted by a wart but pass over a callus — the most reliable clinical sign.
• Thrombosed capillaries ("black dots"): Pinpoint black or red-brown dots within the wart surface represent thrombosed dermal capillary loops that have been pushed up into the stratum corneum. Pathognomonic when present.
• Punctate bleeding on paring: When a plantar wart is pared with a scalpel, capillary bleeding occurs (bleeding sign); a callus does not bleed on paring.

Dermoscopy

• Reveals a mosaic of red or brownish dots (capillary loops) surrounded by white halo pattern in common and plantar warts. Flat warts show a homogeneous, speckled reddish-brown pattern. Dermoscopy significantly improves diagnostic accuracy over naked-eye examination.

Histopathology (when diagnosis uncertain)

• Hyperkeratosis, parakeratosis, acanthosis, papillomatosis, and pathognomonic koilocytes (vacuolated keratinocytes with pyknotic, eccentric nuclei, and perinuclear clearing) in the upper stratum spinosum and granulosum.

Differential Diagnosis

• Callus/corn: Smooth surface, skin lines intact, no black dots, no punctate bleeding on paring.
• Molluscum contagiosum: Smooth, dome-shaped papules with central umbilication (dell); caused by poxvirus, not HPV.
• Seborrheic keratosis: Waxy, stuck-on appearance; usually in older adults; no black dots; milia-like cysts on dermoscopy.
• Squamous cell carcinoma: Must be excluded in non-healing, rapidly growing, or recurrent lesions especially in immunocompromised patients or in unusual sites (sole, perianal, nail).
• Amelanotic melanoma: Can rarely mimic a plantar wart; biopsy any lesion that bleeds, grows rapidly, or fails to respond to treatment.

Treatment Options

No treatment is 100% effective because none can eliminate HPV from the body — only the clinical lesion is destroyed. Recurrence is common. Treatment choice depends on wart type, location, patient age, immune status, and patient preference.

Salicylic Acid (Highest Evidence for Cutaneous Warts)

• Available over the counter (17% solution or 40% pads) and in prescription concentrations (up to 60%).
• Mechanism: keratolytic — softens and dissolves the hyperkeratotic wart tissue, gradually reducing wart size. May also stimulate local immune response through irritation.
• Application: Soak wart in warm water 5 minutes, pare with pumice stone or emery board, apply salicylic acid, allow to dry, cover with tape. Repeat daily for 8–12 weeks. Avoid surrounding skin (petrolatum barrier).
• Cochrane review (Kwok et al., 2012, PMID 22786532): systematic review of 85 RCTs; salicylic acid shows ~75% cure rates vs ~48% for placebo at 3 months in cutaneous warts. Most effective when applied consistently and combined with paring.
• Best for: common hand warts, plantar warts, mosaic warts in cooperative patients. Not for facial warts or genital warts.

Cryotherapy (Liquid Nitrogen)

• Mechanism: Liquid nitrogen applied to the wart surface (spray gun or cotton-tipped applicator) freezes tissue to −196°C. The freeze-thaw cycle damages cellular membranes and causes ischemic necrosis. More importantly, cryotherapy creates an inflammatory reaction that exposes HPV antigens to immune surveillance, triggering local cell-mediated immunity that helps prevent recurrence.
• Treatment protocol: freeze 10–30 seconds, allow complete thaw, repeat immediately (two freeze-thaw cycles per session); return every 2–4 weeks for repeat treatment.
• Cure rates: approximately 60–70% for hand warts with 3–6 treatments; lower for thick plantar warts (requiring aggressive paring before freezing).
• Side effects: pain during and after treatment (significant — important to warn patients), blistering (expected — tells patient it worked), temporary hypopigmentation or hyperpigmentation.
• Not for use in pregnancy (insufficient safety data), over digits with compromised circulation (Raynaud's, severe peripheral arterial disease), or in children who cannot tolerate the pain.

Cantharidin ("Beetle Juice")

• Extract from the blister beetle Lytta vesicatoria; applied by a physician in the office (not available OTC in the US) in concentrations of 0.7–1%.
• Mechanism: inhibits mitochondrial function in acantholytic keratinocytes, causing suprabasal blistering that undermines the wart.
• Applied in-office, covered with tape for 4–6 hours, washed off. A blister forms in 24–48 hours; the wart lifts off the skin as the blister roof.
• Painless at application (making it useful in children and needle-phobic patients); pain develops as the blister forms. No permanent scarring.
• Cure rates of ~65–85% with 1–3 treatments; widely used by pediatric dermatologists.

Candida Antigen Immunotherapy

• Intralesional injection of Candida albicans antigen (a widely available skin-test antigen) into the largest wart stimulates a Th1 cell-mediated immune response that cross-reacts against HPV-infected cells.
• Particularly effective for multiple or recalcitrant warts because the systemic immune stimulation can clear distant, non-injected warts.
• Cure rates: 56–80% in observational studies; RCT evidence limited but growing.
• Treatment schedule: injection every 3–4 weeks, up to 3 sessions. Side effects: local injection pain, erythema, sometimes flu-like symptoms from the immune activation.
• Useful for: patients with multiple warts, mosaic plantar warts, immunocompetent patients with recalcitrant disease.

Duct-Tape Occlusion — Evidence Controversy

• The 2002 Wenner RCT (PMID 12361440): 61 children with warts randomized to duct tape vs cryotherapy for 2 months. Duct tape achieved 85% complete resolution vs 60% for cryotherapy (P=0.05). Widely cited; generated enormous public interest.
• The 2006 Focht RCT (PMID 16365281): 103 adult patients; moleskin (similar non-specific occlusion) vs duct tape — NO significant difference; 21% vs 22% clearance. Critically undermined the Wenner results.
• Current evidence assessment: The specific duct-tape effect is unproven and probably not superior to simple occlusion or placebo. However, daily occlusion may help concentrate moisture, soften the wart for paring, and possibly trigger minor immune stimulation through skin irritation. Safe to try as low-cost adjunct; should not replace established treatments.

Genital Wart Treatments

• Imiquimod 5% cream (Aldara): Toll-like receptor agonist that activates innate immunity and induces interferon-alpha; applied by the patient 3 times weekly for up to 16 weeks. Clears condylomata in ~50% after 1 course; lower recurrence than destructive methods.
• Podophyllotoxin 0.5% solution or 0.15% cream (Condyline, Warticon): Purified active constituent of podophyllin; cytotoxic, inhibits cell division; patient-applied twice daily for 3 days followed by 4 days off, for up to 4 cycles. Not safe in pregnancy.
• Trichloroacetic acid (TCA) 80–90%: Office procedure; chemical cautery; applied carefully to external warts only; effective for small external condylomata. Safe in pregnancy.
• Sinecatechins (Veregen) 15% ointment: Standardized catechin extract from green tea; patient-applied 3× daily for up to 16 weeks; works via antioxidant, antiviral, and immune-modulating mechanisms. FDA-approved for external genital warts.
• Surgical excision, CO2 laser, or electrosurgery: For large, extensive, or recalcitrant condylomata; performed under local anesthesia.

Natural and Experimental Approaches

• Garlic (Allicin): Crushed garlic applied topically has been studied in small RCTs. A 2005 Iranian trial (Dehghani et al., PMID 15892728) found chloroform extract of garlic cleared common warts in 100% of treated patients vs 0% control in 12 weeks. Mechanism: allicin has direct antiviral activity. The trial is small; replication needed. Practical use: crush a fresh garlic clove, apply juice to wart, cover with tape overnight. Can cause significant skin irritation.
• Apple cider vinegar (acetic acid): Popular home remedy; the acidic pH may have keratolytic effect similar to weak salicylic acid. No clinical RCTs. Risk of chemical burn if applied incorrectly to surrounding skin or mucosa. Not recommended for genital warts.
• Zinc sulfate oral supplementation: Several small RCTs from Middle Eastern centers show 10 mg/kg/day oral zinc sulfate (maximum 600 mg/day) achieves 60–80% wart clearance, possibly by enhancing cell-mediated immunity. A 2009 review (Al-Gurairi et al.) supports this approach. Nausea is the main side effect; tolerate with food. Intriguing immunomodulatory mechanism; needs larger trials.
• Tea tree oil: Anecdotal reports of clearance with daily application; terpinen-4-ol has antiviral properties in vitro. No controlled trials for warts. Safe as adjunct if does not irritate skin.
• Cimetidine (H2 blocker): Used at immunomodulatory doses (30–40 mg/kg/day in children) for multiple warts; mechanism involves histamine receptor–mediated enhancement of cell-mediated immunity (Th1 shift). Small studies show clearance in 30–80%; larger placebo-controlled trials have been negative. Sometimes used in recalcitrant pediatric cases as adjunct due to excellent safety profile.

Immune Clearance and Spontaneous Resolution

• Most warts clear spontaneously as the immune system eventually recognizes and clears the HPV infection. Prospective studies in children show 65% of warts resolve within 2 years without treatment; 25% persist beyond 5 years.
• Mechanism of spontaneous clearance: CD4+ Th1 lymphocytes recognize HPV E2, E6, and E7 peptides presented on MHC-II, activating CD8+ cytotoxic T cells that destroy HPV-infected keratinocytes. Clearance is often sudden and complete — a cluster of warts disappears over weeks after months of persistence.
• Immunocompromised patients do not self-clear: HIV, organ transplant recipients, primary immunodeficiencies — HPV is not controlled, warts proliferate and recur relentlessly, and the risk of malignant transformation (especially with cutaneous HPV in epidermodysplasia verruciformis spectrum) is substantially elevated.
• The "watchful waiting" option: For asymptomatic warts in children, observation without treatment is a valid first choice — avoiding painful treatments while waiting for immune clearance. The probability of natural resolution is highest in younger patients and those with recently acquired, non-hyperkeratotic warts.
• Psychological impact of waiting: Parents (and adults) often have anxiety about contagion, cancer risk (low in low-risk HPV types), and social embarrassment. Realistic counseling — "most go away on their own but it can take 1–2 years" — is as important as prescribing treatment.

Complications

• Nail damage (subungual and periungual warts): HPV infection under or around the nail can cause nail dystrophy, onycholysis (nail lifting from nail bed), and permanent nail deformity if deeply invasive. Treatment is particularly challenging given proximity to the nail matrix.
• Recalcitrant warts in immunocompromised patients: Warts in HIV/AIDS, transplant recipients, and patients on immunosuppressants are notoriously treatment-resistant, multiply extensively, and carry a risk of malignant transformation. Reduction of immunosuppression is the most effective intervention where medically feasible.
• Squamous cell carcinoma (SCC): Malignant transformation is rare for low-risk HPV types but can occur in immunocompromised patients (especially with cutaneous EV-associated HPV types on sun-exposed skin) and in anogenital warts associated with high-risk HPV types that become co-infected with HPV-16/18. Any wart that grows unusually rapidly, bleeds, ulcerates, or fails standard treatment warrants biopsy.
• Plantar wart disability: Severely painful plantar warts limit ambulation and quality of life. School absenteeism in children and work limitation in adults are documented consequences of inadequately treated plantar disease.
• Recurrent respiratory papillomatosis (RRP): HPV-6 and HPV-11 can cause papillomas on the larynx, trachea, and bronchi — the result of perinatal HPV transmission. A rare but serious condition in children requiring repeated surgical procedures (laser or microdebrider ablation) to maintain an open airway. Highly aggressive HPV-11–associated RRP may progress to life-threatening disease.
• Psychological burden: Visible warts on hands and face cause embarrassment, teasing (in children), and avoidance of social activities. Genital warts cause relationship and sexual anxiety, stigma, and depression.

Prevention and Contagion Control

• HPV vaccination: The nonavalent Gardasil-9 vaccine covers HPV types 6, 11 (genital warts), 16, 18, 31, 33, 45, 52, and 58 (cervical/oropharyngeal cancer types). Most effective when given before sexual debut (recommended at ages 9–12 in the US; catch-up through age 26; shared decision-making 27–45). Provides ~90% protection against genital warts and near-complete protection against cervical cancer due to covered types. Does not protect against existing HPV infection.
• Avoid skin-to-skin contact with visible warts: Do not share towels, razors, nail clippers, or shoes with a person who has warts. Autoinoculation prevention: keep warts covered, do not pick, bite, or scratch warts.
• Foot hygiene for plantar warts: Wear flip-flops in communal showers, pool decks, and locker rooms (HPV survives in warm, moist environments). Dry feet thoroughly; keep skin intact (microtrauma is the entry point).
• Condoms for genital warts: Male condoms reduce (but do not eliminate) genital HPV transmission because HPV infects perigenital skin not covered by a condom. Female condoms provide more complete coverage. Partner notification and testing are appropriate for genital wart diagnosis.
• Shaving over flat warts: Avoid dry-shaving over flat wart areas — use an electric razor, or switch shaving direction to avoid spread. Consider laser epilation in recurrent facial flat warts in women.
• Immunocompromised patients: Ensure HPV vaccination is complete before starting immunosuppression (where feasible). Regular skin surveillance by dermatology for cutaneous wart burden, atypical lesions, and early malignancy.

Key Research Papers

1. Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012;(9):CD001781. PMID 22786532
2. Wenner R, Askari SK, Cham PMH, et al. Duct tape for the treatment of common warts in adults: a double-blind randomized controlled trial. Arch Dermatol. 2007;143(3):309-313. PMID 16365281
3. Focht DR, Spicer C, Fairchok MP. The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch Pediatr Adolesc Med. 2002;156(10):971-974. PMID 12361440
4. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010;118(1 Suppl):S12-17. PMID 20728208
5. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55-70. PMID 23199966
6. Al-Gurairi FT, Al-Waiz M, Sharquie KE. Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial. Br J Dermatol. 2002;146(3):423-431. PMID 11966693
7. Dehghani F, Merat A, Panjehshahin MR, Handjani F. Healing effect of garlic extract on warts and corns. Int J Dermatol. 2005;44(7):612-615. PMID 15892728
8. Micali G, Dall'Oglio F, Nasca MR, Tedeschi A. Management of cutaneous warts: an evidence-based approach. Am J Clin Dermatol. 2004;5(5):311-317. PMID 15113186
9. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer — burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;(31):3-13. PMID 14020759
10. Gibbs S, Harvey I. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2006;(3):CD001781. PMID 16625589
11. Passeron T, Lacour JP, Fontas E, Ortonne JP. Treatment of oral florid papillomatosis with intralesional injections of cidofovir: report of two cases. J Eur Acad Dermatol Venereol. 2005;19(6):762-764. PMID 16207248
12. Brodell RT, Johnson SM. Curettage, cryosurgery, and topical therapy of viral warts. Dermatol Surg. 2003;29(4):353-356. PMID 12558651

Back to Table of Contents

PubMed Searches

Curated PubMed topic searches of peer-reviewed literature on warts and HPV.

1. PubMed: HPV warts cryotherapy treatment
2. PubMed: HPV keratinocyte pathogenesis
3. PubMed: Salicylic acid verruca RCT
4. PubMed: Condyloma acuminata treatment
5. PubMed: HPV immune evasion spontaneous resolution
6. PubMed: Candida antigen immunotherapy warts
7. PubMed: Plantar wart treatment outcomes
8. PubMed: HPV vaccination prevention warts
9. PubMed: Flat warts verruca plana treatment
10. PubMed: Imiquimod genital warts RCT

Back to Table of Contents

Connections

• Scabies
• Fungal Infections
• Melanoma
• Herpes Simplex
• Eczema
• Psoriasis
• Acne
• HIV/AIDS
• Urticaria (Hives)
• Zinc
• Garlic
• Green Tea
• Vitamin C
• Vitamin D3
• Vitiligo
• Seborrheic Dermatitis

Back to Table of Contents

×

Featured Videos